A trial to study the safety and tolerability of pirfenidone and nintedanib in patients with pulmonary fibrosis.

Trial Profile

A trial to study the safety and tolerability of pirfenidone and nintedanib in patients with pulmonary fibrosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
  • Indications Pulmonary fibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Mar 2017 Results (n=186) assessing drug tolerability and adverse events of pirfenidone and nintedanib therapy, published in the Respirology
    • 05 Jul 2016 New trial record
    • 18 May 2016 Results (n=107) presented at the 112th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top